Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-29

Inhibikase Therapeutics (IKT)

CEO Mark Iwicki was paid $30,586,007 in fiscal year 2025 (SEC filing 0001193125-26-197177 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$30,586,007
Mark Iwicki total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
73.88%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Mark Iwicki (Chief Executive Officer and Director), FY2025 total compensation $30,586,007 (base salary $624,208) [exec_comp, SEC accession 0001193125-26-197177, filed 2026-04-30]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

IKT's next annual pay disclosure, estimated April 30, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Mark Iwicki$624,208$0$0$29,429,299$532,500$0$0$30,586,007
Chief Executive Officer and Director
Chris Cabell, M.D.429,167006,764,872281,250007,475,289
President and Head of Research and Development
David McIntyre347,216004,899,661272,813005,519,690
Chief Financial Officer
Milton Werner, Ph.D.728,9790040,44931,54302,092803,063
Former President and Chief Executive Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Mark Iwicki$30,586,007———
Chris Cabell, M.D.7,475,289———
David McIntyre5,519,690———
Milton Werner, Ph.D.803,0637,980,623—↓ −7,177,560

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Inhibikase Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper IKT reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against IKT
No companies currently name IKT as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Chris Cabell, M.D.President$7,475,289
Mark IwickiCEO$30,586,007
Milton Werner, Ph.D.Executive$803,063
David McIntyreCFO$5,519,690
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Dr. David CannerIndependent Director$448,011
Dr. Roy FreemanIndependent Director$31,400
Mr. Amit MunshiIndependent Director$542,394
Mr. Arvind KushIndependent Director$537,344
Mr. Dennis BermanIndependent Director$306,426
Mr. Roberto BelliniIndependent Director$572,560
Mr. Vincent AurentzIndependent Director$500,531
02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Mark IwickiOPTION2025-02-21——602,346—$1,452,376
Mark IwickiOPTION2025-02-17——2,392,388—3,821,661
Mark IwickiOPTION2025-02-14——12,668,989—20,237,762
Christopher CabellOPTION2025-02-21——2,810,000—6,764,872
David McIntyreOPTION2025-04-14——3,142,967—4,899,661
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Mark Iwicki$0$0$25,511,7990.0%
Christopher Cabell006,764,8720.0%
David McIntyre004,899,6610.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Mark IwickiOption3,462,6372.35—
Mark IwickiOption476,8572.97—
Mark IwickiOption6,837,1802.35—
Mark IwickiOption1,420,4802.35—
David McIntyreOption1,775,5392—
David McIntyreOption1,367,4282—
05

Incentive-plan design — the Compensation Discussion & Analysis

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultant—
Clawback policytrue
Anti-hedging—
Anti-pledging—
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-2661,237,30421,648,671222,74173.88%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-2673.88%a

a. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Mr. Roberto BelliniIndependent · Nominating/Governance (Chair)$103,750—$468,810——$572,560
Mr. Amit MunshiIndependent · Compensation102,050—440,344——542,394
Mr. Arvind KushIndependent · Compensation · Audit (Chair)97,000—440,344——537,344
Mr. Vincent AurentzIndependent · Nominating/Governance · Audit65,133—435,398——500,531
Dr. David CannerIndependent · Nominating/Governance64,600—383,411——448,011
Mr. Dennis BermanIndependent · Compensation (Chair) · Audit90,000—216,426——306,426
Dr. Roy FreemanIndependent · Departed during FY31,400—0——31,400
Mark IwickiEmployee director—————0
09

Board fee structure and ownership guideline

Annual cash retainer$60,000
Annual equity retainer$150,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)—
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$553,933
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$553,933

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Inhibikase Therapeutics2025Mark Iwicki$624,208$0$29,429,299$532,500$30,586,007

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Inhibikase Therapeutics in fiscal 2025?
As disclosed, Mark Iwicki (Chief Executive Officer and Director) was the highest-paid executive at Inhibikase Therapeutics in fiscal 2025, with total compensation of $30,586,007.
How did shareholders vote on Inhibikase Therapeutics's executive compensation?
As disclosed, 73.88% of shareholders supported Inhibikase Therapeutics's executive compensation in the latest say-on-pay vote.
How much does Inhibikase Therapeutics spend in total on board compensation for fiscal 2025?
As disclosed, Inhibikase Therapeutics reported total board compensation of $553,933 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Mark IwickiDEF 14A2026-04-300001193125-26-197177Section “Executive Compensation”. As printed: 30,586,007. Filing ↗machine: r2 · c16 · span 621587–621597
2Section 01, Chris Cabell, M.D.DEF 14A2026-04-300001193125-26-197177Section “Executive Compensation”. As printed: 7,475,289. Filing ↗machine: r4 · c16 · span 633751–633760
3Section 01, David McIntyreDEF 14A2026-04-300001193125-26-197177Section “Executive Compensation”. As printed: 5,519,690. Filing ↗machine: r6 · c16 · span 645920–645929
4Section 01, Milton Werner, Ph.D.DEF 14A2026-04-300001193125-26-197177Section “Executive Compensation”. As printed: 803,063. Filing ↗machine: r8 · c16 · span 658069–658076
5Section 03, Mark Iwicki OPTIONDEF 14A2026-04-300001193125-26-197177Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 572684–572693
6Section 03, Mark Iwicki OPTIONDEF 14A2026-04-300001193125-26-197177Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 566642–566651
7Section 03, Mark Iwicki OPTIONDEF 14A2026-04-300001193125-26-197177Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 560622–560632
8Section 03, Christopher Cabell OPTIONDEF 14A2026-04-300001193125-26-197177Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 579035–579044
9Section 03, David McIntyre OPTIONDEF 14A2026-04-300001193125-26-197177Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 585395–585404
10Section 08, Mr. Roberto BelliniDEF 14A2026-04-300001193125-26-197177Section “Director Compensation”. As printed: 572,560. Filing ↗
11Section 08, Mr. Amit MunshiDEF 14A2026-04-300001193125-26-197177Section “Director Compensation”. As printed: 542,394. Filing ↗
12Section 08, Mr. Arvind KushDEF 14A2026-04-300001193125-26-197177Section “Director Compensation”. As printed: 537,344. Filing ↗
13Section 08, Mr. Vincent AurentzDEF 14A2026-04-300001193125-26-197177Section “Director Compensation”. As printed: 500,531. Filing ↗
14Section 08, Dr. David CannerDEF 14A2026-04-300001193125-26-197177Section “Director Compensation”. As printed: 448,011. Filing ↗
15Section 08, Mr. Dennis BermanDEF 14A2026-04-300001193125-26-197177Section “Director Compensation”. As printed: 306,426. Filing ↗
16Section 08, Dr. Roy FreemanDEF 14A2026-04-300001193125-26-197177Section “Director Compensation”. As printed: 31,400. Filing ↗
17Section 08, Mark IwickiDEF 14A2026-04-300001193125-26-197177Section “Director Compensation”. As printed: 0. Filing ↗
18Section 06, 2026 voteForm 8-K2026-06-290001193125-26-286747Item 5.07 · say-on-pay result. As reported: 73.88% (votes for as printed: 61,237,304). Filing ↗
19Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
20Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
21Section 09b board cost (computed)Computed——Cash 553,933 + equity 0 + all other 0 = 553,933, summed across the director compensation table rows.machine: formula: Σ = 553,933
22Inhibikase Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-300001193125-26-197177CEO total compensation as printed in Inhibikase Therapeutics's own proxy. As printed: 30,586,007. Filing ↗machine: r2 · c16 · span 621587–621597

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.